<DOC>
	<DOCNO>NCT00527488</DOCNO>
	<brief_summary>This exploratory study conduct open label single investigational clinical unit . Altogether 52 patient benign prostate hyperplasia ( BPH ) randomly assign receive 4 different treatment degarelix .</brief_summary>
	<brief_title>Explorative Study Degarelix Treatment Benign Prostatic Hyperplasia .</brief_title>
	<detailed_description>The present study aim explore potential currently available formulation degarelix treat BPH short transient lower serum testosterone concentration castration level define 0.5 ng/mL . Two dos two dose regimen ( 32 64 mg administer either single administration two administration separate 14 day ) evaluate 42 day .</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<criteria>Each patient must comply follow inclusion criterion allow randomise study : 1 . Man , 55 75 year age . 2 . Clinical diagnose BPH prostate volume 30 mL , maximal uroflow 12 mL/sec less international prostate sympton score ( IPSS ) 13 screen . 3 . A prostate specific antigen ( PSA ) value le 10 ng/mL clinical evidence adenocarcinoma prostate screening . If biopsy prostate perform , period 6 week allow biopsy patient enrol study . 4 . Has baseline testosterone level 3 ng/mL screen . Any patient meeting one follow exclusion criterion include study : 1 . Previous surgery prostate . 2 . Previous treatment GnRH agonists GnRH antagonist . 3 . Treatment 5alpha reductase inhibitor , e.g. , finasteride ( Prosca® ) dutasteride ( Avodart® ) within past 12 month study . 4 . Treatment alphaadrenergic antagonist , e.g. , terazosin , doxazosin , tamsulosin , alfuzosin within 2 week prior Screening part II ( Part I , IPSS perform Screening part I ) . 5 . Treatment drug modify testosterone level function within 12 week Screening visit part II ( Part I , IPSS perform Screening part I ) .</criteria>
	<gender>Male</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Benign Prostate Hyperplasia</keyword>
	<keyword>BPH</keyword>
	<keyword>PK/PD</keyword>
	<keyword>GnRH antagonist</keyword>
</DOC>